Turtle and team conducted a phase I/II clinical trial in patients with refractory B-ALL in which CD8+ and CD4+ T cell subsets were separately modified to express a CD19-targeted CAR (FMC63-based) formulated in a defined ratio of CD4+:CD8+ CAR-T cells. This evidence concerns the gene CD8A and precursor B-cell acute lymphoblastic leukemia.